Group Art Unit: Unassigned

Examiner: Unassigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Bonner et al.

Application No. Unassigned

Filed: November 7, 2001

For: A KIT FOR DETERMINING DNA

DOUBLE-STRANDED BREAKS WITH

ANTI-y-H2A ANTIBODIES

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form 1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form 1449 is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.



In re Appln. of Bonner et al. Application No. Unassigned

	after (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes <i>one</i> of:						
		the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).					
	\Box	the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).					
	under and o 37 CF	the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance 37 CFR 1.311, or an action that otherwise closes prosecution in the application, n or before payment of the issue fee, and includes the Statement under R 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as th in 37 CFR 1.17(p) (see "Fees" below).					
	payme contai 37 CF \$180 a NOTE: May 29	the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before ent of the issue fee, and within thirty days of receiving each item of information ned in the Information Disclosure Statement, and includes the Statement under R 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of as set forth in 37 CFR 1.17(p) (see "Fees" below). This is for original applications except applications for a design patent, filed on or after 0, 2000, wherein a paper containing only an Information Disclosure Statement in compliance CFR 1.97 and 1.98 is being filed.					
Copie	s of the	References					
	Attacl	s of the references listed on the enclosed Form 1449 are enclosed herewith. ned to each reference not in the English language is a concise explanation of the nce pursuant to 37 CFR 1.98(a)(3).					
	A cop	y of the foreign search report is enclosed herewith.					
	parent furnis submi The laccord Proce- relied	eferences listed on the enclosed Form 1449 were previously identified in the application(s) of the present application, and copies of the references were hed at that time. Accordingly, additional copies of the references are not atted herewith, so as not to burden the file with duplicate copies of references. Examiner is respectfully requested to carefully review the references in dance with the requirements set out in the Manual of Patent Examining dure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) upon for an earlier filing date under 35 USC 120 in which copies of the nces were previously furnished are set out below:					

In re Appln. of Bonner et al. Application No. Unassigned

for that purpose.)

1

U.S. APPL	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
1. 09/351,721	July 12, 1999		X	
2.				
3.				

3.					
_3			.		L
State	ment under 37 CFR	1.97(e)			
	Information Discloration Discloration patent office	hereby states that each sure Statement was fince in a counterpart foreing of the Information	rst cited in a gn patent appl	ny commun ication not r	ication from a
	Information Disclosoffice in a counte undersigned after n Information Disclosoff	hereby states that no sure Statement was cited rpart foreign patent appaking reasonable inquir osure Statement was bore than three months nt.	l in a communicular plication, and ry, no item of item	cation from a to the known to t	a foreign patent owledge of the contained in the designated in
State	ment under 37 CFR	1.704(d)			
	Information Disclosoffice in a counterjany individual desi	hereby states that each sure Statement was cited part application and that gnated in 37 CFR 1.56(d) Disclosure Statement.	l in a communi this commun	cation from a ication was i	a foreign patent not received by
Fees					
	No fee is owed by the IDS Fee of \$18	he applicant(s). 80 under 37 CFR 1.17(p)	is enclosed he	erewith.	
Meth	od of Payment of Fe	es			
		in the amount of \$ count No. 12-1216 in the is enclosed for that purp		. (A dı	uplicate copy of
Auth	orization to Charge	Additional Fees			
\boxtimes	If any additional fe Deposit Account N	es are owed in connection of the connection of t	on with this co	mmunication communica	n, please charge tion is enclosed

3

In re Appln. of Bonner et al. Application No. Unassigned

Instructions as to Overpayment

\boxtimes	Credit Account No.	12-1216.
	Refund	

Carol Larcher, Reg. No. 35,243 LEYDIG, VOIT & MAYER, LTD. Two Prudential Plaza, Suite 4900

180 North Stetson

Chicago, Illinois 60601-6780 (312) 616-5600 (telephone) (312) 616-5700 (facsimile)

Date: November 7, 2001

IDS (Rev. 2/1/2001)

Please type a plus sign	+) inside this	box —	* 1+

Substitute for form 1449A/B/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

	Complete if Known	a
Application Number	Unassigned	J.S.
Filing Date	November 7, 2001	
First Named Inventor	William M. Bonner	
Group Art Unit	Unassigned	310
Examiner Name	Unassigned	
Attorney Docket Number	214041	

U.S. PATENT DOCUMENTS							
	U.S. Patent Document						
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate	
	AA	5,637,465		Trauth	June 1997		
	AB	5,807,999		Kohtz	Sept.1998		
		, , , , , , , , , , , , , , , , , , , ,	1				
			1				
				-		1	
			 		- "		
							
			+				
			+				
			+				
			+				
							
			+				
						 	
						ļ	
						ļ <u> </u>	
						ļ	
							
	<u> </u>					†	
-	 	1				1	
		 	+				

Examiner Signature	Date Considered	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).



				Complete if Known		
Substitute for fo	orm 1449A/B/PTO			Application Number	Unassigned	
INIE	ORMATION I	חופר	OCUPE	Filing Date	November 7, 2001	
				First Named Inventor	William M. Bonner	
STATEMENT BY APPLICANT				Group Art Unit	Unassigned	
	(Use as many sheet	s as nec	cessarv)	Examiner Name	Unassigned	
Sheet	2	of	2	Attorney Docket Number	214041	

Examin	OTHER - NON PATENT LITERATURE DOCUMENTS xamin Doc Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,						
er Initials	Doc. No.	magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Yes	No*			
	AC	Bonner et al., Molecular Biology of the Cell, 9, 320A (1998) (Abstract)					
	ΑD	Carrier et al., J. of Immunological Methods, 181, 177-186 (1995)					
	ΑE	Mannironi et al., Nucleic Acids Research, 17(22), 9113-9126 (1989)					
	ΑF	Muller et al., Molecular Immunology, 23(6), 593-601 (1986)					
	AG	Soto et al., Immunology Letters, 48, 209-214 (1995)					
	АН	Rogakou et al., Proceedings of the American Association for Cancer Research Annual, 38 (April, 1997) (Abstract No. 2313)					
	ΑI	Rogakou et al., <i>Molecular Biology of the Cell</i> , 9, 109A (1998) (Abstract)		-			
-	ΑJ	Rogakou et al., The Journal of Biological Chemistry, 273(10), 5858-5868 (1998)					
	AK	Rogakou et al., <i>Proceedings of the American Association for Cancer Research Annual</i> , 39 (March, 1998) (Abstract No. 3927)					
	AL	Ueda et al., Developmental Biology, 169, 210-217 (1995)					
•							
			1				
							
	 		T				
	<u> </u>		<u> </u>				
	 		\vdash				
				1			
				\vdash			

Examiner Signature	Date Considered	

^{*} A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

⁺ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).